馃毃馃摚馃摚 #ESMO26 presidential: @niazi_Dr7 Adding darolutamide to ADT + RT dramatically 猬囷笍 risk of metastasis or death in high-risk localized prostate cancer. Phase 3 DASL-HiCaP = 58% 猬囷笍 in MFS (HR 0.42) + early OS signal (HR 0.88). #ProstateCancer #RadOnc聽#pcsm @ChrisSweens1
532 views 路 23 likes 路 11 reposts 路 0 replies
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.orgSource: Shankar Siva 路 x.com